Literature DB >> 26760185

Differentiating Transition Zone Cancers From Benign Prostatic Hyperplasia by Quantitative Multiparametric Magnetic Resonance Imaging.

Osama Elbuluk1, Naira Muradyan, Joanna Shih, Marcelino Bernardo, Sandeep Sankineni, Maria J Merino, Bradford J Wood, Peter A Pinto, Peter L Choyke, Baris Turkbey.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the value of quantitative diffusion and perfusion parameters to aid in discriminating between transition zone carcinomas and benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS: Twenty-four transition zone cancers and BPH nodules were contoured on T2-weighted magnetic resonance imaging (MRI), apparent diffusion coefficient (ADC) maps, and raw dynamic contrast-enhanced (DCE) MRI. Benign prostatic hyperplasia nodules were then stratified into 2 groups based on the presence or absence of a capsule. Apparent diffusion coefficient values, per-voxel Ktrans, kep, vp, and ve were all compared across all groups.
RESULTS: Average ADCs (×10 mm/s) were 1019.22, 1338.11, and 1272.46 for cancer, encapsulated BPH, and nonencapsulated BPH, respectively. Both subgroups of BPH were found to be significantly different than that of cancer (P < 0.05). No individual DCE-MRI parameter was significantly different between cancer and either BPH group. The area under the curve for ADC alone was 0.83, and no individual DCE imaging parameter improved the area under the curve of ADC.
CONCLUSIONS: Apparent diffusion coefficient may play a role in distinguishing TZ cancers from non-encapsulated BPH nodules that closely resemble cancer.

Entities:  

Mesh:

Year:  2016        PMID: 26760185      PMCID: PMC7787362          DOI: 10.1097/RCT.0000000000000353

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  29 in total

1.  Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA.

Authors:  A R Padhani; C J Gapinski; D A Macvicar; G J Parker; J Suckling; P B Revell; M O Leach; D P Dearnaley; J E Husband
Journal:  Clin Radiol       Date:  2000-02       Impact factor: 2.350

2.  A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds.

Authors:  Vijay Shah; Thomas Pohida; Baris Turkbey; Haresh Mani; Maria Merino; Peter A Pinto; Peter Choyke; Marcelino Bernardo
Journal:  Rev Sci Instrum       Date:  2009-10       Impact factor: 1.523

3.  Microvascularity in benign prostatic hyperplasia.

Authors:  R E Deering; S A Bigler; M Brown; M K Brawer
Journal:  Prostate       Date:  1995-03       Impact factor: 4.104

Review 4.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

5.  Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging.

Authors:  Caroline M A Hoeks; Thomas Hambrock; Derya Yakar; Christina A Hulsbergen-van de Kaa; Ton Feuth; J Alfred Witjes; Jurgen J Fütterer; Jelle O Barentsz
Journal:  Radiology       Date:  2012-11-09       Impact factor: 11.105

Review 6.  Advances in magnetic resonance imaging: how they are changing the management of prostate cancer.

Authors:  Alessandro Sciarra; Jelle Barentsz; Anders Bjartell; James Eastham; Hedvig Hricak; Valeria Panebianco; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-02-23       Impact factor: 20.096

7.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging.

Authors:  Jurgen J Fütterer; Stijn W T P J Heijmink; Tom W J Scheenen; Jeroen Veltman; Henkjan J Huisman; Pieter Vos; Christina A Hulsbergen-Van de Kaa; J Alfred Witjes; Paul F M Krabbe; Arend Heerschap; Jelle O Barentsz
Journal:  Radiology       Date:  2006-09-11       Impact factor: 11.105

8.  Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging.

Authors:  Aytekin Oto; Arda Kayhan; Yulei Jiang; Maria Tretiakova; Cheng Yang; Tatjana Antic; Farid Dahi; Arieh L Shalhav; Gregory Karczmar; Walter M Stadler
Journal:  Radiology       Date:  2010-09-15       Impact factor: 11.105

9.  Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging.

Authors:  Marc R Engelbrecht; Henkjan J Huisman; Robert J F Laheij; Gerrit J Jager; Geert J L H van Leenders; Christina A Hulsbergen-Van De Kaa; Jean J M C H de la Rosette; Johan G Blickman; Jelle O Barentsz
Journal:  Radiology       Date:  2003-08-27       Impact factor: 11.105

10.  Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread.

Authors:  J E McNeal; E A Redwine; F S Freiha; T A Stamey
Journal:  Am J Surg Pathol       Date:  1988-12       Impact factor: 6.394

View more
  4 in total

1.  Utility of quantitative apparent diffusion coefficient measurements and normalized apparent diffusion coefficient ratios in the diagnosis of clinically significant peripheral zone prostate cancer.

Authors:  Tan B Nguyen; Alexander Ushinsky; Albert Yang; Michael Nguyentat; Sara Fardin; Edward Uchio; Chandana Lall; Thomas Lee; Roozbeh Houshyar
Journal:  Br J Radiol       Date:  2018-06-21       Impact factor: 3.039

2.  Diagnosis of transition zone prostate cancer using T2-weighted (T2W) MRI: comparison of subjective features and quantitative shape analysis.

Authors:  Satheesh Krishna; Nicola Schieda; Matthew Df McInnes; Trevor A Flood; Rebecca E Thornhill
Journal:  Eur Radiol       Date:  2018-08-13       Impact factor: 5.315

3.  Development and validation of a logistic regression model to distinguish transition zone cancers from benign prostatic hyperplasia on multi-parametric prostate MRI.

Authors:  Yuji Iyama; Takeshi Nakaura; Kazuhiro Katahira; Ayumi Iyama; Yasunori Nagayama; Seitaro Oda; Daisuke Utsunomiya; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2017-03-13       Impact factor: 5.315

4.  Zinc-sensitive MRI contrast agent detects differential release of Zn(II) ions from the healthy vs. malignant mouse prostate.

Authors:  M Veronica Clavijo Jordan; Su-Tang Lo; Shiuhwei Chen; Christian Preihs; Sara Chirayil; Shanrong Zhang; Payal Kapur; Wen-Hong Li; Luis M De Leon-Rodriguez; Angelo J M Lubag; Neil M Rofsky; A Dean Sherry
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-25       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.